An eight-week, double-blind, placebo controlled, multicenter study with escitalopram (10 mg Qd) as positive control, evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A [amibegron] (350 mg q12) in outpatients with MDD.

Trial Profile

An eight-week, double-blind, placebo controlled, multicenter study with escitalopram (10 mg Qd) as positive control, evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A [amibegron] (350 mg q12) in outpatients with MDD.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2009

At a glance

  • Drugs Amibegron; Escitalopram
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms ORION
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Jan 2009 Planned number of patients changed from 450 to 468 as reported by ClinicalTrials.gov.
    • 08 Jan 2009 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 13 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top